Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
<p><strong>Background</strong></p> Although biological therapies have transformed the outlook for those with rheumatoid arthritis, there is a lack of any meaningful response in approximately 40% of patients. The role of B cells in rheumatoid arthritis pathogenesis is well rec...
Main Authors: | Humby, F, Durez, P, Buch, MH, Lewis, MJ, Bombardieri, M, John, C, Rizvi, H, Warren, L, Peel, J, Fossati-Jimack, L, Hands, RE, Giorli, G, Rivellese, F, Cañete, JD, Taylor, PC, Sasieni, P, Fonseca, JE, Choy, E, Pitzalis, C |
---|---|
Format: | Journal article |
Language: | English |
Published: |
NIHR Journals Library
2022
|
Similar Items
-
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
by: Frances Humby, et al.
Published: (2022-08-01) -
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): A stratified, biopsy-driven, multi-centre, randomised, open label, controlled clinical trial - 16 week outcomes
by: Humby, F, et al.
Published: (2021) -
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
by: Rivellese, F, et al.
Published: (2022) -
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure
by: Humby, F, et al.
Published: (2019) -
PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)